Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adial Pharmaceuticals (ADIL) EBT Margin (2022 - 2024)

Adial Pharmaceuticals' EBT Margin history spans 3 years, with the latest figure at 245829800.0% for Q2 2024.

  • For Q2 2024, EBT Margin rose 24582581628.0% year-over-year to 245829800.0%; the TTM value through Dec 2024 reached 8015.12%, down 3844621.0%, while the annual FY2021 figure was 41978.33%, 39374127.0% up from the prior year.
  • EBT Margin for Q2 2024 was 245829800.0% at Adial Pharmaceuticals, up from 3933.34% in the prior quarter.
  • Across five years, EBT Margin topped out at 245829800.0% in Q2 2024 and bottomed at 56849.25% in Q1 2022.
  • The 3-year median for EBT Margin is 3933.34% (2024), against an average of 49151592.06%.
  • The largest YoY upside for EBT Margin was 2000000000bps in 2024 against a maximum downside of 1110751bps in 2024.
  • A 3-year view of EBT Margin shows it stood at 56849.25% in 2022, then surged by 107bps to 3983.72% in 2023, then skyrocketed by 6170759bps to 245829800.0% in 2024.
  • Per Business Quant, the three most recent readings for ADIL's EBT Margin are 245829800.0% (Q2 2024), 3933.34% (Q1 2024), and 3983.72% (Q2 2023).